Rep. Laurel M. Lee Sells Off Shares of Novo Nordisk A/S (NYSE:NVO)

Representative Laurel M. Lee (R-Florida) recently sold shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on May 8th.

Novo Nordisk A/S Trading Up 1.3%

Novo Nordisk A/S stock traded up $0.94 during mid-day trading on Friday, hitting $71.67. The company's stock had a trading volume of 7,345,265 shares, compared to its average volume of 7,144,964. The company has a 50 day moving average of $70.67 and a 200-day moving average of $73.80. The stock has a market cap of $320.00 billion, a PE ratio of 21.20, a P/E/G ratio of 1.36 and a beta of 0.64. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion for the quarter. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on NVO shares. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Finally, Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Novo Nordisk A/S has an average rating of "Hold" and a consensus price target of $112.00.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors have recently made changes to their positions in the company. NorthRock Partners LLC acquired a new stake in shares of Novo Nordisk A/S in the second quarter worth approximately $336,000. Delaney Dennis R boosted its stake in shares of Novo Nordisk A/S by 25.0% in the second quarter. Delaney Dennis R now owns 26,710 shares of the company's stock worth $1,844,000 after acquiring an additional 5,350 shares during the last quarter. Yousif Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 7.0% in the second quarter. Yousif Capital Management LLC now owns 38,849 shares of the company's stock worth $2,681,000 after acquiring an additional 2,553 shares during the last quarter. MGO One Seven LLC boosted its stake in shares of Novo Nordisk A/S by 183.0% in the second quarter. MGO One Seven LLC now owns 50,154 shares of the company's stock worth $3,462,000 after acquiring an additional 32,432 shares during the last quarter. Finally, Hazlett Burt & Watson Inc. boosted its stake in Novo Nordisk A/S by 14.7% during the second quarter. Hazlett Burt & Watson Inc. now owns 11,829 shares of the company's stock worth $817,000 after buying an additional 1,516 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

About Representative Lee

Laurel Lee (Republican Party) is a member of the U.S. House, representing Florida's 15th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Lee (Republican Party) is running for re-election to the U.S. House to represent Florida's 15th Congressional District. She declared candidacy for the 2026 election. Laurel Lee earned undergraduate and law degrees from the University of Florida. Lee's career experience includes working as an attorney with Carlton Fields, P.A., an assistant federal public defender and assistant U.S. attorney with the United States District Court for the Middle District of Florida, and a law clerk to James S. Moody on the United States District Court for the Middle District of Florida. Lee resigned on May 16, 2022.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.